This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Guo, Y.-J. Articles by Sy, M.-S. Search for Related Content PubMed PubMed Citation Articles by Guo, Y.-J. Articles by Sy, M.-S.

Potential Use of Soluble CD44 in Serum as Indicator of Tumor Burden and Metastasis in Patients with Gastric or Colon Cancer

Institute of Pathology, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106 [Y-J. G., J. M., M-S. S.]; Eastern Institute of Hepatobiliary Surgery and Eastern Hospital for Hepatobiliary Surgery, Shanghai 200433 [Y-J. G., G. L., M. W.]; Nafang Immunology and Bio-Technology Center, Nafang University, Tonghe, Guongzhou 510515 [X. W., D. J.],, Peoples Republic of China

¹ To whom requests for reprints should be addressed, at Department of Pathology, Institute of Pathology, Case Western Reserve University School of Medicine. 9th Floor, Biomedical Research Building, 10900 Euclid Ave., Cleveland, OH 44106.

Soluble CD44 is present in the serum of normal individuals (2.7 ± 1.1 nM). The concentration of soluble CD44 in the serum is elevated in patients with advanced gastric (24.2 ± 9.8 nM) or colon cancer (30.8 ± 11 nM). Serum CD44 concentration correlated with tumor metastasis and tumor burden. Surgical resection of tumors resulted in decreases in serum CD44 levels. By Western blot analysis, monoclonal anti-CD44 antibody reacted with a major protein with molecular weight between 130,000 and 190,000. In addition, two proteins with molecular weights of 72,000 and 80,000 can also be identified. Therefore, different CD44 isoforms may be present in the serum of cancer patients. Serum CD44 concentrations may be an indicator of tumor burden and metastasis in patients with malignant diseases.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 8/ 9/93. Accepted 11/10/93.

This article has been cited by other articles:

				S. P. Becerra, L. A. Perez-Mediavilla, J. E. Weldon, S. Locatelli-Hoops, P. Senanayake, L. Notari, V. Notario, and J. G. Hollyfield Pigment Epithelium-derived Factor Binds to Hyaluronan: MAPPING OF A HYALURONAN BINDING SITE J. Biol. Chem., November 28, 2008; 283(48): 33310 - 33320. [Abstract] [Full Text] [PDF]

				K. N. Sugahara, T. Hirata, T. Tanaka, S. Ogino, M. Takeda, H. Terasawa, I. Shimada, J.-i. Tamura, G. B. ten Dam, T. H. van Kuppevelt, et al. Chondroitin Sulfate E Fragments Enhance CD44 Cleavage and CD44-Dependent Motility in Tumor Cells Cancer Res., September 1, 2008; 68(17): 7191 - 7199. [Abstract] [Full Text] [PDF]

				T. A. D'Amico, K. R. Brooks, M.-B. M. Joshi, D. Conlon, J. Herndon II, R. P. Petersen, and D. H. Harpole Jr Serum Protein Expression Predicts Recurrence in Patients With Early-Stage Lung Cancer After Resection Ann. Thorac. Surg., June 1, 2006; 81(6): 1982 - 1987. [Abstract] [Full Text] [PDF]

				K. N. Sugahara, T. Hirata, H. Hayasaka, R. Stern, T. Murai, and M. Miyasaka Tumor Cells Enhance Their Own CD44 Cleavage and Motility by Generating Hyaluronan Fragments J. Biol. Chem., March 3, 2006; 281(9): 5861 - 5868. [Abstract] [Full Text] [PDF]

				E. J. Franzmann, E. P. Reategui, K. L. Carraway, K. L. Hamilton, D. T. Weed, and W. J. Goodwin Salivary Soluble CD44: A Potential Molecular Marker for Head and Neck Cancer Cancer Epidemiol. Biomarkers Prev., March 1, 2005; 14(3): 735 - 739. [Abstract] [Full Text] [PDF]

				H. Nakamura, N. Suenaga, K. Taniwaki, H. Matsuki, K. Yonezawa, M. Fujii, Y. Okada, and M. Seiki Constitutive and Induced CD44 Shedding by ADAM-Like Proteases and Membrane-Type 1 Matrix Metalloproteinase Cancer Res., February 1, 2004; 64(3): 876 - 882. [Abstract] [Full Text] [PDF]

				X.-M. Xu, Y. Chen, J. Chen, S. Yang, F. Gao, C. B. Underhill, K. Creswell, and L. Zhang A Peptide with Three Hyaluronan Binding Motifs Inhibits Tumor Growth and Induces Apoptosis Cancer Res., September 15, 2003; 63(18): 5685 - 5690. [Abstract] [Full Text] [PDF]

				S.-C. Lee, H.-J. Harn, T.-S. Lin, K.-T. Yeh, Y.-C. Liu, C.-S. Tsai, and Y.-L. Cheng Prognostic significance of CD44v5 expression in human thymic epithelial neoplasms Ann. Thorac. Surg., July 1, 2003; 76(1): 213 - 218. [Abstract] [Full Text] [PDF]

				K. Komura, S. Sato, M. Fujimoto, M. Hasegawa, and K. Takehara Elevated levels of circulating CD44 in patients with systemic sclerosis: association with a milder subset Rheumatology, October 1, 2002; 41(10): 1149 - 1154. [Abstract] [Full Text] [PDF]

				M. Suzuki, H. Kobayashi, M. Fujie, T. Nishida, M. Takigawa, N. Kanayama, and T. Terao Kunitz-type Protease Inhibitor Bikunin Disrupts Phorbol Ester-induced Oligomerization of CD44 Variant Isoforms Containing Epitope v9 and Subsequently Suppresses Expression of Urokinase-type Plasminogen Activator in Human Chondrosarcoma Cells J. Biol. Chem., March 1, 2002; 277(10): 8022 - 8032. [Abstract] [Full Text] [PDF]

				M. Kajita, Y. Itoh, T. Chiba, H. Mori, A. Okada, H. Kinoh, and M. Seiki Membrane-Type 1 Matrix Metalloproteinase Cleaves Cd44 and Promotes Cell Migration J. Cell Biol., May 28, 2001; 153(5): 893 - 904. [Abstract] [Full Text] [PDF]

				A. C. Woodman, S. Goodison, M. Drake, J. Noble, and D. Tarin Noninvasive Diagnosis of Bladder Carcinoma by Enzyme-linked Immunosorbent Assay Detection of CD44 Isoforms in Exfoliated Urothelia Clin. Cancer Res., June 1, 2000; 6(6): 2381 - 2392. [Abstract] [Full Text]

				N. L. W. Van Hal, G. A. M. S. Van Dongen, C. B. M. Ten Brink, K.-H. Heider, I. Rech-Weichselbraun, G. B. Snow, and R. H. Brakenhoff Evaluation of Soluble CD44v6 as a Potential Serum Marker for Head and Neck Squamous Cell Carcinoma Clin. Cancer Res., November 1, 1999; 5(11): 3534 - 3541. [Abstract] [Full Text] [PDF]

				W Reinisch, K-H Heider, G Oberhuber, C Dejaco, M Mullner, G R Adolf, and C Gasche Poor diagnostic value of colonic CD44v6 expression and serum concentrations of its soluble form in the differentiation of ulcerative colitis from Crohn's disease Gut, September 1, 1998; 43(3): 375 - 382. [Abstract] [Full Text] [PDF]

				Q. Yu, B. P. Toole, and I. Stamenkovic Induction of Apoptosis of Metastatic Mammary Carcinoma Cells In Vivo by Disruption of Tumor Cell Surface CD44 Function J. Exp. Med., December 15, 1997; 186(12): 1985 - 1996. [Abstract] [Full Text] [PDF]

				R. Ristamaki, H. Joensuu, K. Lappalainen, L. Teerenhovi, and S. Jalkanen Elevated Serum CD44 Level Is Associated With Unfavorable Outcome in Non-Hodgkin's Lymphoma Blood, November 15, 1997; 90(10): 4039 - 4045. [Abstract] [Full Text] [PDF]

				Q. Yu and B. P. Toole A New Alternatively Spliced Exon between v9 and v10 Provides a Molecular Basis for Synthesis of Soluble CD44 J. Biol. Chem., August 23, 1996; 271(34): 20603 - 20607. [Abstract] [Full Text] [PDF]